Treatment of Cognitive and Negative Symptoms in Schizophrenia With N-acetylcysteine

PHASE4CompletedINTERVENTIONAL
Enrollment

51

Participants

Timeline

Start Date

February 6, 2017

Primary Completion Date

January 31, 2023

Study Completion Date

January 31, 2023

Conditions
SchizophreniaCognitive DeficitsSchizophrenia; Negative Type
Interventions
DRUG

N-acetylcysteine

N-acetylcysteine is a safe, widely available supplement currently FDA-approved for treatment of acetaminophen antidote and as a mucolytic. It has effects on glutamate in the brain via the NMDA receptor as well as the glutathione antioxidant system (it is a precursor to glutathione).

OTHER

Treatment as Usual

Treatment for schizophrenia which may include medications, therapy, or other types of treatment as determined by the subject's VA or community psychiatrist or mental health treatment team

Trial Locations (1)

90024

UCLA Semel Institute for Neuroscience and Human Behavior, Los Angeles

All Listed Sponsors
lead

University of California, Los Angeles

OTHER

NCT02505477 - Treatment of Cognitive and Negative Symptoms in Schizophrenia With N-acetylcysteine | Biotech Hunter | Biotech Hunter